Skip to main content
SpringerLink
Log in

Antibiotikaprophylaxe in der Urologie

Antibiotic prophylaxis in urology

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Das Ziel der perioperativen Antibiotikaprophylaxe ist die Vermeidung von postoperativen Gewebeinfektionen sowie bei urologischen Prozeduren auch die Vermeidung von Harnwegsinfektionen. Die Indikation für eine antibiotische Prophylaxe orientiert sich an einer Reihe von Risikofaktoren, wie dem Grad der potenziellen Kontamination des Operationsfelds, einer verlängerten Operationsdauer, Fremdkörperimplantationen oder Komorbiditäten des einzelnen Patienten, und umfasst in der Regel eine einmalige antibiotische Gabe rechtzeitig vor dem operativen Eingriff. Die Antibiotikaprophylaxe trägt zum Gesamtantibiotikaverbrauch und damit zur Antibiotikaresistenzentstehung bei. Sie kann die Hygiene und operative Sorgfalt eines Eingriffs nicht ersetzen.

Abstract

The aim of perioperative antibiotic prophylaxis is the prevention of surgical site infections and urinary tract infections during urological procedures. The indication for antibiotic prophylaxis comprises several risk factors such as the degree of contamination of the operative site, duration of surgery, implantation of devices and comorbidities of the individual patient. In general this involves a single antibiotic administration before the operative procedure. The antibiotic prophylaxis is part of the total antibiotic consumption and thus a factor contributing to emergence of antibiotic resistance. It is not a substitute for hygiene measures or operative precision.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Rovera F, Diurni M, Dionigi G et al (2005) Antibiotic prophylaxis in colorectal surgery. Expert Rev Anti Infect Ther 3(5):787–795

    Article  PubMed  Google Scholar 

  2. Wacha H, Hoyme U, Isenmann R et al (2010) Perioperative Antibiotika-Prophylaxe. Empfehlungen einer Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Chemotherapie Journal 19:70–84

    Google Scholar 

  3. Grabe M, Botto H, Cek M et al (2010) Preoperative assessment of the patient, risk factor identification and tentative classification of surgical field contamination in urologic surgery. In: Naber KG, Schaeffer AJ, Heyns CF et al (Hrsg) Urogenital infections. European Association of Urology, Arnhem, The Netherlands, S 667–685

  4. American Society of Anesthesiologists. ASA physical status classification. http://asahq.org/clinical/physicalstatus.htm

  5. Woodfield JC, Beshay NM, Pettigrew RA et al (2007) American Society of Anesthesiologists classification of physical status as a predictor of wound infection. ANZ J Surg 77(9):738–741

    Article  PubMed  Google Scholar 

  6. Mangram AJ, Horan TC, Pearson ML et al (1999) Guideline for prevention of surgical site infection. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 27(2):97–132; quiz 3–4; discussion 96

    Article  PubMed  CAS  Google Scholar 

  7. Wagenlehner FM, Schmiemann G, Hoyme U et al (2011) National S 3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients. Urologe A 50(2):153–169

    Article  PubMed  CAS  Google Scholar 

  8. Mariappan P, Smith G, Bariol SV et al (2005) Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. J Urol 173(5):1610–1614

    Article  PubMed  Google Scholar 

  9. Lindstedt S, Lindstrom U, Ljunggren E et al (2006) Single-dose antibiotic prophylaxis in core prostate biopsy: impact of timing and identification of risk factors. Eur Urol 50(4):832–837

    Article  PubMed  Google Scholar 

  10. Robinson MR, Arudpragasam ST, Sahgal SM et al (1982) Bacteraemia resulting from prostatic surgery: the source of bacteria. Br J Urol 54(5):542–546

    Article  PubMed  CAS  Google Scholar 

  11. Cruse PJ, Foord R (1973) A five-year prospective study of 23,649 surgical wounds. Arch Surg 107(2):206–210

    Article  PubMed  CAS  Google Scholar 

  12. Nam RK, Saskin R, Lee Y et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183(3):963–968

    Article  PubMed  Google Scholar 

  13. Roach MB, Figueroa TE, McBride D et al (1991) Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy. Urology 38(1):84–87

    Article  PubMed  CAS  Google Scholar 

  14. Wagenlehner FM, Wagenlehner C, Schinzel S, Naber KG (2005) Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. Eur Urol 47(4):549–556

    Article  PubMed  CAS  Google Scholar 

  15. Berry A, Barratt A (2002) Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol 167(2 Pt 1):571–577

    Article  PubMed  Google Scholar 

  16. Pessaux P, Atallah D, Lermite E et al (2005) Risk factors for prediction of surgical site infections in „clean surgery“. Am J Infect Control 33(5):292–298

    Article  PubMed  Google Scholar 

  17. Naber CK, Al-Nawas B, Baumgartner H et al (2007) Prophylaxe der infektiösen Endokarditis. Kardiologie 1:243–250

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: F.W. hat Vergütungen für Vorträge, Forschungsvorhaben und Mitwirkung in External Advisory Boards erhalten von Astellas, Bayer Vital, Bionorica, Calixa, Cerexa, MerLion, OM-Pharma, Janssen-Cilag, Johnson&Johnson, Pharmacia, Pierre Fabre, Rosen-Pharma, Sanofi-Aventis, Strathmann und Zambon.

Author information

Authors and Affiliations

  1. Klinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Gießen und Marburg, Standort Gießen, Rudolf-Buchheim-Str. 7 , 35392, Gießen, Deutschland

    F.M.E. Wagenlehner & W. Weidner

  2. Department of Urology, Skåne University Hospital, Malmö, University of Lund, Lund, Schweden

    M. Grabe

  3. Technische Universität, München, Deutschland

    K.G. Naber

  4. Department of Urology, Aarhus University Hospital, Skejby, Aarhus, Dänemark

    T.E. Bjerklund Johansen

  5. Zentrum für Kardiovaskuläre Medizin, Elisabeth-Krankenhaus Essen, Essen, Deutschland

    C.K. Naber

Authors
  1. F.M.E. Wagenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Grabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K.G. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T.E. Bjerklund Johansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C.K. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Weidner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F.M.E. Wagenlehner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagenlehner, F., Grabe, M., Naber, K. et al. Antibiotikaprophylaxe in der Urologie. Urologe 50, 1469–1480 (2011). https://doi.org/10.1007/s00120-011-2661-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-011-2661-0

Schlüsselwörter

Keywords

Search

Navigation